JAM-A as a prognostic factor and new therapeutic target in multiple myeloma

[1]  A. Keller,et al.  Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease. , 2016, Bone.

[2]  B. Nico,et al.  Microenvironment drug resistance in multiple myeloma: emerging new players , 2016, Oncotarget.

[3]  Y. Furukawa,et al.  Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma , 2016, International Journal of Hematology.

[4]  L. Hofbauer,et al.  The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease , 2016, PloS one.

[5]  D. Scott,et al.  Tension on JAM-A activates RhoA via GEF-H1 and p115 RhoGEF , 2016, Molecular biology of the cell.

[6]  B. Barlogie,et al.  Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. , 2016, Blood.

[7]  T. Himi,et al.  Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma , 2016, Oncotarget.

[8]  S. Watt,et al.  Junctional Adhesion Molecule‐A Is Highly Expressed on Human Hematopoietic Repopulating Cells and Associates with the Key Hematopoietic Chemokine Receptor CXCR4 , 2016, Stem cells.

[9]  M. Reagan,et al.  Multiple myeloma in the marrow: pathogenesis and treatments , 2016, Annals of the New York Academy of Sciences.

[10]  F. Zhan,et al.  Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus , 2015, Oncotarget.

[11]  A. Hopkins,et al.  Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. , 2015, Annals of translational medicine.

[12]  Kristina Schwamborn,et al.  In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma , 2015, EMBO molecular medicine.

[13]  Xiaojun Luo,et al.  Junctional adhesion molecule-A, an epithelial-mesenchymal transition inducer, correlates with metastasis and poor prognosis in human nasopharyngeal cancer. , 2015, Carcinogenesis.

[14]  Funian Lu,et al.  Dysregulation of JAM-A plays an important role in human tumor progression. , 2014, International journal of clinical and experimental pathology.

[15]  T. Suda,et al.  Jam1a – Jam2a interactions regulate haematopoietic stem cell fate through Notch signalling , 2014, Nature.

[16]  William A. Flavahan,et al.  High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. , 2014, Cell reports.

[17]  Min Zhang,et al.  Overexpression of JAM-A in Non-Small Cell Lung Cancer Correlates with Tumor Progression , 2013, PloS one.

[18]  C. Germer,et al.  Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging. , 2013, The Journal of surgical research.

[19]  C. Bailly,et al.  A novel role for junctional adhesion molecule‐A in tumor proliferation: Modulation by an anti‐JAM‐A monoclonal antibody , 2013, International journal of cancer.

[20]  Lieping Chen,et al.  Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma , 2013, Leukemia.

[21]  P. L. Bergsagel,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.

[22]  A. Rosenwald,et al.  Non-Invasive Imaging Provides Spatiotemporal Information on Disease Progression and Response to Therapy in a Murine Model of Multiple Myeloma , 2012, PloS one.

[23]  Andreas Beilhack,et al.  Mapping immune processes in intact tissues at cellular resolution. , 2012, The Journal of clinical investigation.

[24]  U. Gündüz,et al.  Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  池亀 彰茂.  Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors , 2012 .

[26]  N. Halama,et al.  The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications , 2011, British journal of haematology.

[27]  P. Tassone,et al.  Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. , 2011, Blood.

[28]  M. Dimopoulos,et al.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.

[29]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[30]  A. Zernecke,et al.  Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. , 2009, Blood.

[31]  P. Sham,et al.  Elevated plasma level of soluble F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) in hypertension. , 2009, American journal of hypertension.

[32]  E. Severson,et al.  Junctional adhesion molecule A interacts with Afadin and PDZ-GEF2 to activate Rap1A, regulate beta1 integrin levels, and enhance cell migration. , 2009, Molecular biology of the cell.

[33]  Y. Furukawa,et al.  Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma , 2009, Oncogene.

[34]  菅野 安喜.  Junctional adhesion molecule-A, JAM-A, is a novel cell surface marker for long-term repopulating hematopoietic stem cells , 2009 .

[35]  A. Miyajima,et al.  Junctional adhesion molecule-A, JAM-A, is a novel cell-surface marker for long-term repopulating hematopoietic stem cells. , 2008, Blood.

[36]  E. Dejana,et al.  The role of junctional adhesion molecules in vascular inflammation , 2007, Nature Reviews Immunology.

[37]  J. Hernández,et al.  Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. , 2004, Blood.

[38]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[39]  Yulia Nefedova,et al.  Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. , 2004, Blood.

[40]  H. Steininger,et al.  Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. , 2001, The hematology journal : the official journal of the European Haematology Association.

[41]  W. Dalton,et al.  Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.

[42]  T. Kita,et al.  Cutting edge: combined treatment of TNF-alpha and IFN-gamma causes redistribution of junctional adhesion molecule in human endothelial cells. , 1999, Journal of immunology.

[43]  W. Dalton,et al.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. , 1999, Blood.

[44]  E. Dejana,et al.  Junctional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily That Distributes at Intercellular Junctions and Modulates Monocyte Transmigration , 1998, The Journal of cell biology.

[45]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[46]  John Calvin Reed,et al.  The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  F. Sánchez‐Madrid,et al.  Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4 , 1991 .